Pharmaceutical composition, methods for treating and uses thereof
AssigneeBoehringer Ingelheim International GmbH
InventorsEric Williams MAYOUX, Rolf GREMPLER, Thomas KLEIN
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of metabolic disorders in an overweight or obese patient characterized in that empagliflozin and one or more antiobesity drugs are administered to the patient.
Claims13
A method for slowing the progression of, delaying or treating of pre-diabetes in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A method for preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, hyperinsulinemia and metabolic syndrome in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A method for preventing, slowing the progression of, delaying or treating of an onset of type 2 diabetes mellitus in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A method for treating of overweight or obesity in a patient diagnosed of having one or more conditions selected from the group consisting of pre-diabetes, type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, hyperinsulinemia and metabolic syndrome comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A method for improving glycemic control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A method for preventing, slowing, delaying or reversing progression from impaired glucose tolerance, impaired fasting blood glucose, insulin resistance or from metabolic syndrome to type 2 diabetes mellitus in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A method for preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabetes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, dyslipidemia, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis, in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A method for reducing body weight and/or body fat, or preventing an increase in body weight and/or body fat, or facilitating a reduction in body weight and/or body fat, in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A method for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of ectopic fat, in particular liver fat, in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.
A pharmaceutical composition comprising empagliflozin and one or more antiobesity drugs and one or more pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.